154 related articles for article (PubMed ID: 29296819)
1. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.
Spiegel JY; McNamara C; Kennedy JA; Panzarella T; Arruda A; Stockley T; Sukhai M; Thomas M; Bartoszko J; Ho J; Siddiq N; Maze D; Schimmer A; Schuh A; Sibai H; Yee K; Claudio J; Devlin R; Minden MD; Kamel-Reid S; Gupta V
Blood Adv; 2017 Sep; 1(20):1729-1738. PubMed ID: 29296819
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].
Tan YX; Luo J; Huang JX; Luo DM; Liang HY; Zhou X; Liu XL; Xu N
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):323-329. PubMed ID: 35680632
[No Abstract] [Full Text] [Related]
3. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
Loscocco GG; Rotunno G; Mannelli F; Coltro G; Gesullo F; Pancani F; Signori L; Maccari C; Esposito M; Paoli C; Vannucchi AM; Guglielmelli P
Am J Hematol; 2024 Jan; 99(1):68-78. PubMed ID: 37846894
[TBL] [Abstract][Full Text] [Related]
4. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.
Gangat N; Begna KH; Al-Kali A; Hogan W; Litzow M; Pardanani A; Tefferi A
Am J Hematol; 2023 Feb; 98(2):282-289. PubMed ID: 36349465
[TBL] [Abstract][Full Text] [Related]
5. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
Salit RB; Deeg HJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
[TBL] [Abstract][Full Text] [Related]
6. [The role of driver and subclonal mutations in pathogenesis of primary myelofibrosis].
Mózes R; Gángó A; Boha Z; Csomor J; Bödör C
Magy Onkol; 2017 Mar; 61(1):36-45. PubMed ID: 28273187
[TBL] [Abstract][Full Text] [Related]
7. Targeted deep sequencing in primary myelofibrosis.
Tefferi A; Lasho TL; Finke CM; Elala Y; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Blood Adv; 2016 Dec; 1(2):105-111. PubMed ID: 29296803
[TBL] [Abstract][Full Text] [Related]
8. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of Primary Myelofibrosis in the Genomic Era.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
[TBL] [Abstract][Full Text] [Related]
11. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
[TBL] [Abstract][Full Text] [Related]
12. Momelotinib therapy for myelofibrosis: a 7-year follow-up.
Tefferi A; Barraco D; Lasho TL; Shah S; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Blood Cancer J; 2018 Mar; 8(3):29. PubMed ID: 29515114
[TBL] [Abstract][Full Text] [Related]
13. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
14. Highly variable mutational profile of ASXL1 in myelofibrosis.
Sorigué M; Ribera JM; García O; Cabezón M; Vélez P; Marcé S; Xicoy B; Fernández C; Buch J; Cortes M; Plensa E; Gallardo D; Boqué C; Feliu E; Zamora L
Eur J Haematol; 2016 Oct; 97(4):331-5. PubMed ID: 26714837
[TBL] [Abstract][Full Text] [Related]
15. Targeted deep sequencing in polycythemia vera and essential thrombocythemia.
Tefferi A; Lasho TL; Guglielmelli P; Finke CM; Rotunno G; Elala Y; Pacilli A; Hanson CA; Pancrazzi A; Ketterling RP; Mannarelli C; Barraco D; Fanelli T; Pardanani A; Gangat N; Vannucchi AM
Blood Adv; 2016 Nov; 1(1):21-30. PubMed ID: 29296692
[TBL] [Abstract][Full Text] [Related]
16. Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor.
Gangat N; Begna KH; Al-Kali A; Hogan W; Litzow M; Pardanani A; Tefferi A
Blood Cancer J; 2023 Jan; 13(1):3. PubMed ID: 36599841
[TBL] [Abstract][Full Text] [Related]
17. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
Aguirre LE; Jain A; Ball S; Ali NA; Volpe VO; Tinsley-Vance S; Sallman D; Sweet K; Lancet J; Padron E; Yun S; Kuykendall A; Komrokji R
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38548563
[TBL] [Abstract][Full Text] [Related]
18. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?
Guglielmelli P; Rotunno G; Pacilli A; Vannucchi AM
Curr Hematol Malig Rep; 2015 Dec; 10(4):380-7. PubMed ID: 26431835
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
[TBL] [Abstract][Full Text] [Related]
20. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
Tamari R; Rapaport F; Zhang N; McNamara C; Kuykendall A; Sallman DA; Komrokji R; Arruda A; Najfeld V; Sandy L; Medina J; Litvin R; Famulare CA; Patel MA; Maloy M; Castro-Malaspina H; Giralt SA; Weinberg RS; Mascarenhas JO; Mesa R; Rondelli D; Dueck AC; Levine RL; Gupta V; Hoffman R; Rampal RK
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1142-1151. PubMed ID: 30625392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
